Evelo Biosciences’ $45 Million Common Stock Offering

Latham & Watkins LLP represented Evelo Biosciences in the offering.

Evelo Biosciences, Inc., a clinical stage biotechnology company developing orally delivered, systemically acting biologic therapies, has announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock, at a public offering price of $3.75 per share, before underwriting discounts and commissions. Evelo also granted the underwriters a 30-day option, solely to cover over-allotments, if any, to purchase up to an additional 1,800,000 shares of its common stock.

The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, are expected to be approximately $45,000,000 million, excluding any exercise of the underwriters’ option to purchase additional shares. All of the shares in the offering are to be sold by Evelo.

Latham & Watkins LLP represented Evelo Biosciences, Inc. in the offering with a capital markets team led by partners Peter Handrinos (Picture) and Wesley Holmes, with associates Adam Johnson and Angel Marcial.

Involved fees earner: Peter Handrinos – Latham & Watkins; Wesley Holmes – Latham & Watkins; Adam Johnson – Latham & Watkins; Angel Marcial – Latham & Watkins;

Law Firms: Latham & Watkins;

Clients: Evelo Biosciences;


Author: Ambrogio Visconti